Key regions: United Kingdom, Brazil, Europe, France, Canada
The Anti-Fibrinolytic Drugs market in D-A-CH, consisting of Germany, Austria, and Switzerland, has been steadily growing in recent years.
Customer preferences: Patients suffering from bleeding disorders have been the primary customers for Anti-Fibrinolytic Drugs. However, the market has expanded to include patients undergoing surgeries and those with traumatic injuries. The preference for these drugs is due to their ability to prevent excessive bleeding and reduce the need for blood transfusions.
Trends in the market: The Anti-Fibrinolytic Drugs market in D-A-CH is witnessing an increase in demand due to the rise in the number of surgeries being performed. Germany, being the largest market in the region, is driving this growth due to the increasing number of cardiac and orthopedic surgeries. The market is also witnessing a surge in the number of trauma cases, further driving the demand for these drugs.
Local special circumstances: Germany, being the largest market in the region, has a well-established healthcare system, which has been a significant factor in the growth of the Anti-Fibrinolytic Drugs market. The country has a high number of hospitals, and the government's focus on providing better healthcare facilities has led to an increase in the number of surgeries performed. Additionally, the aging population in Germany has also contributed to the growth of the market.
Underlying macroeconomic factors: The Anti-Fibrinolytic Drugs market in D-A-CH is expected to continue its growth trajectory due to the increasing number of surgeries being performed, the rise in the number of trauma cases, and the aging population. However, the market may face challenges due to the high cost of these drugs and the availability of alternative treatments. The ongoing COVID-19 pandemic has also affected the market, leading to a decline in the number of surgeries being performed. Nevertheless, the market is expected to recover in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
